简 体
繁 體
English
About Us
XW Laboratories Inc. (XW Labs) is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders.  In September 2014 we completed our Series A financing with Kleiner Perkins Caulfield Byers/China (KPCB) as leading investor, along with JNJ Venture and WuXi Pharma Venture. We strive to become a leading China-based R&D company with its primary focus on the China market and via collaboration with other companies for foreign markets.

Dr. Jia-Ning Xiang, co-founder of XW Labs, is an experienced R&D veteran with more than two-decade drug discovery and management experience in large pharmaceutical company and small biotech. Major accomplishments include participation or leading the research team for successfully identifying 9 development candidate compounds that entered clinical trials with one compound approved by FDA and PMDA (Japan). Our R&D team consists of highly motivated individuals with diverse expertise backgrounds, which constitute our competitive advantages in our effort in discovering novel medicines for patients worldwide.
XW Laboratories is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company is registered in Cayman Islands and has its subsidiary conducting R&D activities in Wuhan China. In September 2014 we completed our Series A financing with Kleiner Perkins Caulfield Byers/China (KPCB), WuXi Pharma Venture and a global pharma venture as our main investors. We strive to become a leading China-based R&D company with its primary focus on the China market and via collaboration with other companies for foreign markets.

The co-founder of XW Laboratories is an experienced R&D veteran with more than two-decade drug discovery and management experience in large pharmaceutical company and small biotech. Major accomplishments include participation or leading the research team for successfully identifying 9 development candidate compounds that entered clinical trials with one compound approved by FDA and PMDA (Japan). Our R&D team consists of highly motivated individuals with diverse expertise backgrounds, which constitute our competitive advantages in our effort in discoverying novel medicines for patients worldwide.
 
Copyright 2015 XW Laboratories Inc. All rights reserved.